To determine the effect of rebamipide ophthalmic suspension on optical quality in patients with dry eye with short break-up time (BUT) of the tear film.
Twenty-six eyes of 16 patients with the short BUT type of dry eye were enrolled and treated with 2% rebamipide ophthalmic suspension. At baseline and at 2 and 4 weeks after initiating the treatment, the serial corneal higher-order aberrations (HOAs), BUT, fluorescein staining, and Schirmer test were measured. Patients were asked to complete questionnaires about the changes in dry eye–related ocular symptoms after the treatment.
Before the treatment, the pattern of postblink corneal HOAs for 10 seconds showed a sawtooth pattern, with a marked upward curve that increased after blinking. Treatment with rebamipide for 4 weeks significantly (P < 0.05) improved the postblink corneal HOAs and stabilized the pattern of the corneal HOAs. Significant increases in the tear film BUT were seen 2 and 4 weeks after the treatment (P < 0.001 for both comparisons).
Rebamipide administered to treat the short BUT type of dry eye significantly improved optical quality because of the improvement in tear stability.